NIMBEX

Adverse Events

Drug Profile

Learn More

Reference

About Results

Comments

Nimbex Adverse Events Reported to the FDA Over Time

How are Nimbex adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Nimbex, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Nimbex is flagged as the suspect drug causing the adverse event.

Most Common Nimbex Adverse Events Reported to the FDA

What are the most common Nimbex adverse events reported to the FDA?

Hypotension	56 (4.27%)
Anaphylactic Shock	52 (3.96%)
Drug Ineffective	49 (3.73%)
Bronchospasm	39 (2.97%)
Circulatory Collapse	24 (1.83%)
Erythema	24 (1.83%)
Cardiac Arrest	23 (1.75%)
Stevens-johnson Syndrome	23 (1.75%)
Anaphylactic Reaction	22 (1.68%)
Rash	22 (1.68%)
Urticaria	22 (1.68%)
	Show More
Blood Pressure Decreased	21 (1.6%)
Tachycardia	18 (1.37%)
Respiratory Distress	17 (1.29%)
Acute Respiratory Distress Syndrome	15 (1.14%)
Shock	15 (1.14%)
Toxic Skin Eruption	15 (1.14%)
Oedema	13 (.99%)
Anuria	12 (.91%)
Pleural Effusion	12 (.91%)
Septic Shock	12 (.91%)
Rhabdomyolysis	11 (.84%)
Angioedema	10 (.76%)
Bradycardia	10 (.76%)
Multi-organ Failure	10 (.76%)
Oxygen Saturation Decreased	10 (.76%)
Pyrexia	10 (.76%)
Renal Failure	10 (.76%)
Arterial Thrombosis	9 (.69%)
Generalised Erythema	9 (.69%)
Laryngeal Oedema	9 (.69%)
Renal Failure Acute	9 (.69%)
Sinus Tachycardia	9 (.69%)
Cardio-respiratory Arrest	8 (.61%)
Hypoxia	8 (.61%)
Intestinal Ischaemia	8 (.61%)
Propofol Infusion Syndrome	8 (.61%)
Anaesthetic Complication	7 (.53%)
Dyspnoea	7 (.53%)
Haemodynamic Instability	7 (.53%)
Hypersensitivity	7 (.53%)
Medication Error	7 (.53%)
Anaphylactoid Reaction	6 (.46%)
Anaphylactoid Shock	6 (.46%)
Coma	6 (.46%)
Face Oedema	6 (.46%)
Fatigue	6 (.46%)
Hepatitis	6 (.46%)
Hypertension	6 (.46%)
Rash Generalised	6 (.46%)
Respiratory Failure	6 (.46%)
Ventricular Fibrillation	6 (.46%)
Acute Respiratory Failure	5 (.38%)
Confusional State	5 (.38%)
Cyanosis	5 (.38%)
Drug Exposure During Pregnancy	5 (.38%)
Dysarthria	5 (.38%)
Flushing	5 (.38%)
Hypocapnia	5 (.38%)
Lung Disorder	5 (.38%)
Lymphopenia	5 (.38%)
Peripheral Ischaemia	5 (.38%)
Pityriasis	5 (.38%)
Proteinuria	5 (.38%)
Rales	5 (.38%)
Rash Erythematous	5 (.38%)
Ventricular Hypokinesia	5 (.38%)
Anxiety	4 (.3%)
Cardiogenic Shock	4 (.3%)
Cytolytic Hepatitis	4 (.3%)
Dermatitis Bullous	4 (.3%)
Enterobacter Infection	4 (.3%)
General Physical Health Deteriorati...	4 (.3%)
Haematuria	4 (.3%)
Hypercapnia	4 (.3%)
Incorrect Dose Administered	4 (.3%)
Mydriasis	4 (.3%)
Pancreatitis Acute	4 (.3%)
Paralysis	4 (.3%)
Paresis	4 (.3%)
Post Procedural Complication	4 (.3%)
Pulmonary Oedema	4 (.3%)
Renal Impairment	4 (.3%)
Skin Test Positive	4 (.3%)
Thrombocytopenia	4 (.3%)
Tryptase Increased	4 (.3%)
Acute Pulmonary Oedema	3 (.23%)
Bacteroides Infection	3 (.23%)
Blood Pressure Systolic Decreased	3 (.23%)
C-reactive Protein Increased	3 (.23%)
Chylothorax	3 (.23%)
Delayed Recovery From Anaesthesia	3 (.23%)
Dermatomyositis	3 (.23%)
Disorientation	3 (.23%)
Fear	3 (.23%)
Glucose Tolerance Impaired	3 (.23%)
Haemoptysis	3 (.23%)
Hepatic Encephalopathy	3 (.23%)
Hyperthermia	3 (.23%)
Hyperthermia Malignant	3 (.23%)
Immunosuppressant Drug Level Increa...	3 (.23%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Nimbex, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Nimbex is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Nimbex

What are the most common Nimbex adverse events reported to the FDA?

Epidermal And Dermal Conditions	131 (9.98%)
Allergic Conditions	96 (7.31%)
Decreased And Nonspecific Blood Pre...	95 (7.24%)
Cardiac Arrhythmias	84 (6.4%)
Respiratory	83 (6.32%)
Therapeutic And Nontherapeutic Effe...	59 (4.49%)
Cardiac And Vascular Investigations	44 (3.35%)
Bronchial Disorders	42 (3.2%)
Renal Disorders	39 (2.97%)
Angiedema And Urticaria	32 (2.44%)
Lower Respiratory Tract Disorders	30 (2.28%)
	Show More
Procedural And Device Related Injur...	30 (2.28%)
Infections - Pathogen Unspecified	20 (1.52%)
Medication Errors	18 (1.37%)
Muscle	18 (1.37%)
Neurological	17 (1.29%)
Body Temperature Conditions	16 (1.22%)
Pleural	15 (1.14%)
Embolism And Thrombosis	14 (1.07%)
Hepatic And Hepatobiliary	14 (1.07%)
Metabolic, Nutritional And Blood Ga...	13 (.99%)
Movement Disorders	13 (.99%)
Vascular	13 (.99%)
Acid-base	12 (.91%)
Anxiety Disorders	12 (.91%)
Immunology And Allergy	11 (.84%)
Upper Respiratory Tract Disorders	11 (.84%)
Bacterial Infectious	10 (.76%)
Deliria	10 (.76%)
Urinary Tract Signs	10 (.76%)
Chemical Injury And Poisoning	8 (.61%)
Gastrointestinal Vascular Condition...	8 (.61%)
White Blood Cell	8 (.61%)
Anemias Nonhemolytic And Marrow Dep...	7 (.53%)
Heart Failures	7 (.53%)
Ocular Neuromuscular	7 (.53%)
Arteriosclerosis, Stenosis, Vascula...	6 (.46%)
Cardiac Disorder Signs	6 (.46%)
Coronary Artery	6 (.46%)
Myocardial	6 (.46%)
Vascular Hypertensive	6 (.46%)
Encephalopathies	5 (.38%)
Gastrointestinal Motility And Defec...	5 (.38%)
Gastrointestinal Signs	5 (.38%)
Platelet	5 (.38%)
Protein And Chemistry Analyses	5 (.38%)
Spleen, Lymphatic And Reticulendoth...	5 (.38%)
Cardiac And Vascular Disorders Cong...	4 (.3%)
Electrolyte And Fluid Balance Condi...	4 (.3%)
Enzyme	4 (.3%)
Exocrine Pancreas Conditions	4 (.3%)
Gastrointestinal Tract Disorders Co...	4 (.3%)
Hepatobiliary	4 (.3%)
Injuries	4 (.3%)
Obstetric And Gynecological Therape...	4 (.3%)
Oral Soft Tissue Conditions	4 (.3%)
Toxicology And Therapeutic Drug Mon...	4 (.3%)
Bone And Joint Therapeutic Procedur...	3 (.23%)
Congenital And Hereditary	3 (.23%)
Glucose Metabolism Disorders	3 (.23%)
Hematology Investigations	3 (.23%)
Lymphatic Vessel	3 (.23%)
Miscellaneous And Site Unspecified ...	3 (.23%)
Mood Disorders	3 (.23%)
Musculoskeletal And Connective Tiss...	3 (.23%)
Nephropathies	3 (.23%)
Neuromuscular	3 (.23%)
Physical Examination Topics	3 (.23%)
Renal And Urinary Tract Disorders C...	3 (.23%)
Skin Vascular Abnormalities	3 (.23%)
Suicidal And Self-injurious Behavio...	3 (.23%)
Tissue	3 (.23%)
Tongue Conditions	3 (.23%)
Administration Site Reactions	2 (.15%)
Central Nervous System Vascular	2 (.15%)
Coagulopathies And Bleeding Diathes...	2 (.15%)
Fetal And Neonatal	2 (.15%)
Gastrointestinal Stenosis And Obstr...	2 (.15%)
Hematological And Lymphoid Tissue T...	2 (.15%)
Hepatobiliary Therapeutic Procedure...	2 (.15%)
Joint	2 (.15%)
Mental Impairment	2 (.15%)
Neonatal And Perinatal Conditions	2 (.15%)
Ocular Infections, Irritations And ...	2 (.15%)
Product Quality Issues	2 (.15%)
Pulmonary Vascular	2 (.15%)
Seizures	2 (.15%)
Sexual Function And Fertility	2 (.15%)
Skin And Subcutaneous Tissue	2 (.15%)
Testicular And Epididymal	2 (.15%)
Water, Electrolyte And Mineral	2 (.15%)
Bile Duct	1 (.08%)
Changes In Physical Activity	1 (.08%)
Cranial Nerve Disorders	1 (.08%)
Disturbances In Thinking	1 (.08%)
Fatal Outcomes	1 (.08%)
Fungal Infectious	1 (.08%)
Gastrointestinal Therapeutic Proced...	1 (.08%)
Musculoskeletal And Connective Tiss...	1 (.08%)
Musculoskeletal And Soft Tissue Inv...	1 (.08%)
Neurological, Special Senses And Ps...	1 (.08%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Nimbex, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Nimbex is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Nimbex According to Those Reporting Adverse Events

Why are people taking Nimbex, according to those reporting adverse events to the FDA?

Anaesthesia	91
Drug Use For Unknown Indication	56
Induction Of Anaesthesia	43
Product Used For Unknown Indication	37
General Anaesthesia	35
Sedation	26
	Show More
Paralysis	14
Neuromuscular Blockade	13
Surgery	10
Endotracheal Intubation	10
Anaesthesia Procedure	8
Muscle Relaxant Therapy	7
Mechanical Ventilation	6
Unevaluable Event	5
Hypotonia	4
Neuromuscular Blocking Therapy	3
Intubation	2
Prophylaxis	2
Respiratory Failure	2
Septic Shock	2
Sickle Cell Anaemia With Crisis	2
Acute Respiratory Distress Syndrome	2
Renal Failure	1
Spinal Fracture	1
Heart Valve Replacement	1
Drug Exposure During Pregnancy	1
Blepharoplasty	1
Inguinal Hernia	1
Gastric Operation	1
Coronary Artery Bypass	1
Maintenance Of Anaesthesia	1
Tachypnoea	1
Sepsis	1
Convulsion	1
Analgesic Effect	1
Stupor	1
Spinal Anaesthesia	1
Muscle Spasms	1
Feeling Of Relaxation	1
Polytraumatism	1
Antasthmatic Drug Level	1

Drug Labels

Label	Labeler	Effective
Nimbex	Abbott Laboratories	06-AUG-12

Nimbex Case Reports

What Nimbex safety concerns are being reported by doctors and researchers in the medical literature?

About Results

This report contains aggregated drug side effects and adverse events for Nimbex. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Nimbex.